Searched for
BIOLOGICS CONTRACT MANUFACTURING
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata MotorsIndian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: ReportArtificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI s...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Zydus to acquire US biotech firm Agenus’ facilities in CaliforniaZydus Lifesciences is set to acquire Agenus Inc.'s biologics manufacturing facilities in California for $75 million upfront and $50 million...
- Aurobindo Pharma signs pact with MSD to supply biologicals, to invest Rs.1000 crore on plantAurobindo Pharma's subsidiary, TheraNym Biologics Pvt Ltd, has signed a master service agreement with Merck Sharpe & Dohme Singapore for co...
- Aurobindo Pharma arm extends negotiations deadline with MSD for contract manufacturing operationsAurobindo Pharma extends deadline for CuraTeQ Biologics and Merck Sharp & Dohme Singapore negotiations on contract manufacturing operations...
- Samsung Biologics unveils $897 mln manufacturing deals for PfizerSouth Korea's Samsung Biologics announced on Tuesday two deals with Pfizer worth a combined $897 million to manufacture products for the U....
- Pharma CMOs may feel heat as USFDA approves fewer new drugs, GlobalData report saysInflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, stated GlobalData in its latest ...
- Aurobindo Pharma's arm to invest around Rs 300 crore for biologics manufacturing facilitiesThe board of directors of CuraTeQ Biologics Pvt Ltd, at its meeting held on Thursday, approved the expansion of its operations by establish...
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon Biologics wins $90 mn contract from Malaysia to supply human insulinBiocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authori...
- Sun Pharma inks $55.5-mn deal for anti-psoriasis drugSun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.
- Emcure signs deal to manufacture Roche's anti-cancer drugsSwiss drug major Roche, which is often at logger heads with Indian generic drugmakers over patent rights, has made a shift in its strategy.
Load More
